Axogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Axogen and other ETFs, options, and stocks.

About AXGN

Axogen, Inc. engages in the development and marketing of surgical solutions for peripheral nerve regeneration and repair. It provides products and educational resources to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. 

CEO
Michael D. Dale
CEOMichael D. Dale
Employees
622
Employees622
Headquarters
Alachua, Florida
HeadquartersAlachua, Florida
Founded
1977
Founded1977
Employees
622
Employees622

AXGN Key Statistics

Market cap
2.13B
Market cap2.13B
Price-Earnings ratio
-53.88
Price-Earnings ratio-53.88
Dividend yield
—
Dividend yield—
Average volume
1.59M
Average volume1.59M
High today
$37.61
High today$37.61
Low today
$35.82
Low today$35.82
Open price
$37.23
Open price$37.23
Volume
2.32M
Volume2.32M
52 Week high
$52.91
52 Week high$52.91
52 Week low
$15.27
52 Week low$15.27

Stock Snapshot

As of today, Axogen(AXGN) shares are valued at $36.55. The company's market cap stands at 2.13B, with a P/E ratio of -53.88.

As of 2026-10-07, Axogen(AXGN) stock has fluctuated between $35.82 and $37.61. The current price stands at $36.55, placing the stock +2.0% above today's low and -2.8% off the high.

The Axogen(AXGN)'s current trading volume is 2.32M, compared to an average daily volume of 1.59M.

In the last year, Axogen(AXGN) shares hit a 52-week high of $52.91 and a 52-week low of $15.27.

In the last year, Axogen(AXGN) shares hit a 52-week high of $52.91 and a 52-week low of $15.27.

AXGN News

TipRanks 9h
AxoGen initiated with an Overweight at Barclays

Barclays initiated coverage of AxoGen (AXGN) with an Overweight rating and $55 price target The firm rolled out coverage of the medical suppliers and devices gr...

TipRanks 2d
AxoGen should be bought on weakness, says Lake Street

Lake Street expects consistent execution from core Axogen (AXGN) to be complemented by Nerve Tape and recent new commercial wins and thinks consistent execution...

Zacks 2d
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen

AxoGen (AXGN Quick QuoteAXGN - Free Report) has been beaten down lately with too much selling pressure. While the stock has lost 22.6% over the past four...

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

More AXGN News

Simply Wall St 5d
Axogen (NasdaqCM:AXGN) Stock Forecast & Analyst Predictions - Simply Wall Street

...

Axogen (NasdaqCM:AXGN) Stock Forecast & Analyst Predictions - Simply Wall Street
TipRanks 5d
AxoGen Acquires BioCircuit, Expands Peripheral Nerve Portfolio

AxoGen ( (AXGN) ) just unveiled an update. On October 1, 2026, AxoGen completed its acquisition of privately held BioCircuit Technologies, adding NerveTape, th...

TipRanks 6d
AxoGen price target lowered to $53 from $60 at Truist

Truist analyst Ravi Misra lowered the firm’s price target on AxoGen (AXGN) to $53 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model...

People also own

Based on the portfolios of people who own AXGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.